  ADVERSE REACTIONS

  Associated with Discontinuation of Treatment

  Approximately 16% of the 453 patients who received REMERON (mirtazapine) Tablets in US 6-week controlled clinical trials discontinued treatment due to an adverse experience, compared to 7% of the 361 placebo-treated patients in those studies. The most common events (>=1%) associated with discontinuation and considered to be drug related (i.e., those events associated with dropout at a rate at least twice that of placebo) are included in Table 2.

 Table 2: Common Adverse Events Associated With Discontinuation of Treatment in 6-Week US REMERON Trials 
 Adverse Event         Percentage of Patients Discontinuing With Adverse Event   
 REMERON (n=453)                   Placebo (n=361)                
  
  Somnolence≠B-OSE_Labeled_AE                              10.4%                                      2.2%                     
  Nausea≠B-OSE_Labeled_AE                                   1.5%                                       0%                      
           Commonly Observed Adverse Events in US Controlled Clinical Trials
   The most commonly observed adverse events associated with the use of REMERON (mirtazapine) Tablets (incidence of 5% or greater) and not observed at an equivalent incidence among placebo-treated patients (REMERON incidence at least twice that for placebo) are listed in Table 3.

 Table 3: Common Treatment-Emergent Adverse Events Associated With the Use of REMERON in 6-Week US Trials 
 Adverse Event                   Percentage of Patients Reporting Adverse Event   
 REMERON (n=453)                           Placebo (n=361)             
  
  Somnolence≠B-OSE_Labeled_AE                                       54%                                  18%                   
  Increased≠B-OSE_Labeled_AE   Appetite≠I-OSE_Labeled_AE                               17%                                  2%                    
  Weight≠B-OSE_Labeled_AE   Gain≠I-OSE_Labeled_AE                                      12%                                  2%                    
  Dizziness≠B-OSE_Labeled_AE                                        7%                                   3%                    
           Adverse Events Occurring at an Incidence of 1% or More Among REMERON-Treated Patients
   Table 4 enumerates adverse events that occurred at an incidence of 1% or more, and were more frequent than in the placebo group, among REMERON (mirtazapine) Tablets-treated patients who participated in short-term US placebo-controlled trials in which patients were dosed in a range of 5 to 60 mg/day. This table shows the percentage of patients in each group who had at least 1 episode of an event at some time during their treatment. Reported adverse events were classified using a standard COSTART-based dictionary terminology.

 The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side-effect incidence rate in the population studied.

 Table 4: Incidence of Adverse Clinical ExperiencesEvents reported by at least 1% of patients treated with REMERON are included, except the following events, which had an incidence on placebo greater than or equal to REMERON:  headache≠B-NonOSE_AE ,  infection≠B-NonOSE_AE ,  pain≠B-NonOSE_AE ,  chest≠B-NonOSE_AE   pain≠I-NonOSE_AE ,  palpitation≠B-NonOSE_AE ,  tachycardia≠B-NonOSE_AE ,  postural≠B-NonOSE_AE   hypotension≠I-NonOSE_AE ,  nausea≠B-NonOSE_AE ,  dyspepsia≠B-NonOSE_AE ,  diarrhea≠B-NonOSE_AE ,  flatulence≠B-NonOSE_AE ,  insomnia≠B-NonOSE_AE ,  nervousness≠B-NonOSE_AE ,  libido≠B-NonOSE_AE   decreased≠I-NonOSE_AE ,  hypertonia≠B-NonOSE_AE ,  pharyngitis≠B-NonOSE_AE ,  rhinitis≠B-NonOSE_AE ,  sweating≠B-NonOSE_AE ,  amblyopia≠B-NonOSE_AE ,  tinnitus≠B-NonOSE_AE ,  taste≠B-NonOSE_AE   perversion≠I-NonOSE_AE . (>=1%) in Short-Term US Controlled Studies 
 Body System  Adverse Clinical  Experience          REMERON(n=453)                  Placebo(n=361)           
  
    Body≠B-NonOSE_AE   as≠I-NonOSE_AE   a≠I-NonOSE_AE   Whole≠I-NonOSE_AE                           
    Asthenia≠B-OSE_Labeled_AE                                               8%                              5%                 
    Flu≠B-OSE_Labeled_AE   Syndrome≠I-OSE_Labeled_AE                                           5%                              3%                 
    Back≠B-OSE_Labeled_AE   Pain≠I-OSE_Labeled_AE                                              2%                              1%                 
    Digestive≠B-NonOSE_AE   System≠I-NonOSE_AE                          
    Dry≠B-OSE_Labeled_AE   Mouth≠I-OSE_Labeled_AE                                             25%                             15%                 
    Increased≠B-OSE_Labeled_AE   Appetite≠I-OSE_Labeled_AE                                    17%                              2%                 
    Constipation≠B-OSE_Labeled_AE                                          13%                              7%                 
    Metabolic≠B-NonOSE_AE   and≠I-NonOSE_AE   Nutritional≠I-NonOSE_AE   Disorders≠I-NonOSE_AE       
    Weight≠B-OSE_Labeled_AE   Gain≠I-OSE_Labeled_AE                                           12%                              2%                 
    Peripheral≠B-OSE_Labeled_AE   Edema≠I-OSE_Labeled_AE                                       2%                              1%                 
    Edema≠B-OSE_Labeled_AE                                                  1%                              0%                 
    Musculoskeletal≠B-NonOSE_AE   System≠I-NonOSE_AE                    
    Myalgia≠B-OSE_Labeled_AE                                                2%                              1%                 
    Nervous≠B-NonOSE_AE   System≠I-NonOSE_AE                            
    Somnolence≠B-OSE_Labeled_AE                                            54%                             18%                 
    Dizziness≠B-OSE_Labeled_AE                                              7%                              3%                 
    Abnormal≠B-OSE_Labeled_AE   Dreams≠I-OSE_Labeled_AE                                        4%                              1%                 
    Thinking≠B-OSE_Labeled_AE   Abnormal≠I-OSE_Labeled_AE                                      3%                              1%                 
    Tremor≠B-OSE_Labeled_AE                                                 2%                              1%                 
    Confusion≠B-OSE_Labeled_AE                                              2%                              0%                 
    Respiratory≠B-NonOSE_AE   System≠I-NonOSE_AE                        
    Dyspnea≠B-OSE_Labeled_AE                                                1%                              0%                 
    Urogenital≠B-NonOSE_AE   System≠I-NonOSE_AE                         
    Urinary≠B-OSE_Labeled_AE   Frequency≠I-OSE_Labeled_AE                                      2%                              1%                 
            ECG≠B-OSE_Labeled_AE   Changes≠I-OSE_Labeled_AE 
   The electrocardiograms for 338 patients who received REMERON (mirtazapine) Tablets and 261 patients who received placebo in 6-week, placebo-controlled trials were analyzed.  Prolongation≠B-NonOSE_AE   in≠I-NonOSE_AE   QTc≠I-NonOSE_AE   >≠I-NonOSE_AE  =≠I-NonOSE_AE  5≠I-NonOSE_AE  0≠I-NonOSE_AE  0≠I-NonOSE_AE   msec≠I-NonOSE_AE  was not observed among mirtazapine-treated patients;  mean≠B-OSE_Labeled_AE   change≠I-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   QTc≠I-OSE_Labeled_AE  was +1.6 msec for mirtazapine and -3.1 msec for placebo. Mirtazapine was associated with a mean  increase≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   heart≠I-OSE_Labeled_AE   rate≠I-OSE_Labeled_AE  of 3.4 bpm, compared to 0.8 bpm for placebo. The clinical significance of these changes is unknown.

 The effect of REMERON (mirtazapine) on QTc interval was assessed in a clinical randomized trial with placebo and positive (moxifloxacin) controls involving 54 healthy volunteers using exposure response analysis. This trial showed a positive relationship between mirtazapine concentrations and  prolongation≠B-OSE_Labeled_AE   of≠I-OSE_Labeled_AE   the≠I-OSE_Labeled_AE   QTc≠I-OSE_Labeled_AE   interval≠I-OSE_Labeled_AE . However, the degree of  QT≠B-NonOSE_AE   prolongation≠I-NonOSE_AE  observed with both 45 mg (therapeutic) and 75 mg (supratherapeutic) doses of mirtazapine was not at a level generally considered to be clinically meaningful.

   Other Adverse Events Observed During the Premarketing Evaluation of REMERON

  During its premarketing assessment, multiple doses of REMERON (mirtazapine) Tablets were administered to 2796 patients in clinical studies. The conditions and duration of exposure to mirtazapine varied greatly, and included (in overlapping categories) open and double-blind studies, uncontrolled and controlled studies, inpatient and outpatient studies, fixed-dose and titration studies. Untoward events associated with this exposure were recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of untoward events into a smaller number of standardized event categories.

 In the tabulations that follow, reported adverse events were classified using a standard COSTART-based dictionary terminology. The frequencies presented, therefore, represent the proportion of the 2796 patients exposed to multiple doses of REMERON who experienced an event of the type cited on at least 1 occasion while receiving REMERON. All reported events are included except those already listed in Table 4, those adverse experiences subsumed under COSTART terms that are either overly general or excessively specific so as to be uninformative, and those events for which a drug cause was very remote.

 It is important to emphasize that, although the events reported occurred during treatment with REMERON, they were not necessarily caused by it.

 Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring on 1 or more occasions in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients. Only those events not already listed in Table 4 appear in this listing. Events of major clinical importance are also described in the WARNINGS and PRECAUTIONS sections.

    Body≠B-NonOSE_AE   as≠I-NonOSE_AE   a≠I-NonOSE_AE   Whole≠I-NonOSE_AE   :  frequent:   malaise≠B-OSE_Labeled_AE ,  abdominal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  abdominal≠B-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE   acute≠I-OSE_Labeled_AE ;  infrequent:   chills≠B-OSE_Labeled_AE ,  fever≠B-OSE_Labeled_AE ,  face≠B-OSE_Labeled_AE   edema≠I-OSE_Labeled_AE ,  ulcer≠B-OSE_Labeled_AE ,  photosensitivity≠B-OSE_Labeled_AE   reaction≠I-OSE_Labeled_AE ,  neck≠B-OSE_Labeled_AE   rigidity≠I-OSE_Labeled_AE ,  neck≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  abdomen≠B-OSE_Labeled_AE   enlarged≠I-OSE_Labeled_AE ;  rare:   cellulitis≠B-OSE_Labeled_AE ,  chest≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE   substernal≠I-OSE_Labeled_AE .

    Cardiovascular≠B-NonOSE_AE   System≠I-NonOSE_AE   :  frequent:   hypertension≠B-OSE_Labeled_AE ,  vasodilatation≠B-OSE_Labeled_AE ;  infrequent:   angina≠B-OSE_Labeled_AE   pectoris≠I-OSE_Labeled_AE ,  myocardial≠B-OSE_Labeled_AE   infarction≠I-OSE_Labeled_AE ,  bradycardia≠B-OSE_Labeled_AE ,  ventricular≠B-OSE_Labeled_AE   extrasystoles≠I-OSE_Labeled_AE ,  syncope≠B-OSE_Labeled_AE ,  migraine≠B-OSE_Labeled_AE ,  hypotension≠B-OSE_Labeled_AE ;  rare:   atrial≠B-OSE_Labeled_AE   arrhythmia≠I-OSE_Labeled_AE ,  bigeminy≠B-OSE_Labeled_AE ,  vascular≠B-OSE_Labeled_AE   headache≠I-OSE_Labeled_AE ,  pulmonary≠B-OSE_Labeled_AE   embolus≠I-OSE_Labeled_AE ,  cerebral≠B-OSE_Labeled_AE   ischemia≠I-OSE_Labeled_AE ,  cardiomegaly≠B-OSE_Labeled_AE ,  phlebitis≠B-OSE_Labeled_AE ,  left≠B-OSE_Labeled_AE   heart≠I-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE .

    Digestive≠B-NonOSE_AE   System≠I-NonOSE_AE   :  frequent:   vomiting≠B-OSE_Labeled_AE ,  anorexia≠B-OSE_Labeled_AE ;  infrequent:   eructation≠B-OSE_Labeled_AE ,  glossitis≠B-OSE_Labeled_AE ,  cholecystitis≠B-OSE_Labeled_AE ,  nausea≠B-OSE_Labeled_AE  and  vomiting≠B-OSE_Labeled_AE ,  gum≠B-OSE_Labeled_AE   hemorrhage≠I-OSE_Labeled_AE ,  stomatitis≠B-OSE_Labeled_AE ,  colitis≠B-OSE_Labeled_AE ,  liver≠B-OSE_Labeled_AE   function≠I-OSE_Labeled_AE   tests≠I-OSE_Labeled_AE   abnormal≠I-OSE_Labeled_AE ;  rare:   tongue≠B-OSE_Labeled_AE   discoloration≠I-OSE_Labeled_AE ,  ulcerative≠B-OSE_Labeled_AE   stomatitis≠I-OSE_Labeled_AE ,  salivary≠B-OSE_Labeled_AE   gland≠I-OSE_Labeled_AE   enlargement≠I-OSE_Labeled_AE ,  increased≠B-OSE_Labeled_AE   salivation≠I-OSE_Labeled_AE ,  intestinal≠B-OSE_Labeled_AE   obstruction≠I-OSE_Labeled_AE ,  pancreatitis≠B-OSE_Labeled_AE ,  aphthous≠B-OSE_Labeled_AE   stomatitis≠I-OSE_Labeled_AE ,  cirrhosis≠B-OSE_Labeled_AE  of liver,  gastritis≠B-OSE_Labeled_AE ,  gastroenteritis≠B-OSE_Labeled_AE ,  oral≠B-OSE_Labeled_AE   moniliasis≠I-OSE_Labeled_AE ,  tongue≠B-OSE_Labeled_AE   edema≠I-OSE_Labeled_AE .

    Endocrine≠B-NonOSE_AE   System≠I-NonOSE_AE   :  rare:   goiter≠B-OSE_Labeled_AE ,  hypothyroidism≠B-OSE_Labeled_AE .

    Hemic≠B-NonOSE_AE   and≠I-NonOSE_AE   Lymphatic≠I-NonOSE_AE   System≠I-NonOSE_AE   :  rare:   lymphadenopathy≠B-OSE_Labeled_AE ,  leukopenia≠B-OSE_Labeled_AE ,  petechia≠B-OSE_Labeled_AE ,  anemia≠B-OSE_Labeled_AE ,  thrombocytopenia≠B-OSE_Labeled_AE ,  lymphocytosis≠B-OSE_Labeled_AE ,  pancytopenia≠B-OSE_Labeled_AE .

    Metabolic≠B-NonOSE_AE   and≠I-NonOSE_AE   Nutritional≠I-NonOSE_AE   Disorders≠I-NonOSE_AE   :  frequent:   thirst≠B-OSE_Labeled_AE ;  infrequent:   dehydration≠B-OSE_Labeled_AE ,  weight≠B-OSE_Labeled_AE   loss≠I-OSE_Labeled_AE ;  rare:   gout≠B-OSE_Labeled_AE ,  SGOT≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE ,  healing≠B-OSE_Labeled_AE   abnormal≠I-OSE_Labeled_AE ,  acid≠B-OSE_Labeled_AE   phosphatase≠I-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE ,  SGPT≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE ,  diabetes≠B-OSE_Labeled_AE   mellitus≠I-OSE_Labeled_AE ,  hyponatremia≠B-OSE_Labeled_AE .

    Musculoskeletal≠B-NonOSE_AE   System≠I-NonOSE_AE   :  frequent:   myasthenia≠B-OSE_Labeled_AE ,  arthralgia≠B-OSE_Labeled_AE ;  infrequent:   arthritis≠B-OSE_Labeled_AE ,  tenosynovitis≠B-OSE_Labeled_AE ;  rare:   pathologic≠B-OSE_Labeled_AE   fracture≠I-OSE_Labeled_AE ,  osteoporosis≠B-OSE_Labeled_AE   fracture≠I-OSE_Labeled_AE ,  bone≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  myositis≠B-OSE_Labeled_AE ,  tendon≠B-OSE_Labeled_AE   rupture≠I-OSE_Labeled_AE ,  arthrosis≠B-OSE_Labeled_AE ,  bursitis≠B-OSE_Labeled_AE .

    Nervous≠B-NonOSE_AE   System≠I-NonOSE_AE   :  frequent:   hypesthesia≠B-OSE_Labeled_AE ,  apathy≠B-OSE_Labeled_AE ,  depression≠B-OSE_Labeled_AE ,  hypokinesia≠B-OSE_Labeled_AE ,  vertigo≠B-OSE_Labeled_AE ,  twitching≠B-OSE_Labeled_AE ,  agitation≠B-OSE_Labeled_AE ,  anxiety≠B-OSE_Labeled_AE ,  amnesia≠B-OSE_Labeled_AE ,  hyperkinesia≠B-OSE_Labeled_AE ,  paresthesia≠B-OSE_Labeled_AE ;  infrequent:   ataxia≠B-OSE_Labeled_AE ,  delirium≠B-OSE_Labeled_AE ,  delusions≠B-OSE_Labeled_AE ,  depersonalization≠B-OSE_Labeled_AE ,  dyskinesia≠B-OSE_Labeled_AE ,  extrapyramidal≠B-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE ,  libido≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE ,  coordination≠B-OSE_Labeled_AE   abnormal≠I-OSE_Labeled_AE ,  dysarthria≠B-OSE_Labeled_AE ,  hallucinations≠B-OSE_Labeled_AE ,  manic≠B-OSE_Labeled_AE   reaction≠I-OSE_Labeled_AE ,  neurosis≠B-OSE_Labeled_AE ,  dystonia≠B-OSE_Labeled_AE ,  hostility≠B-OSE_Labeled_AE ,  reflexes≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE ,  emotional≠B-OSE_Labeled_AE   lability≠I-OSE_Labeled_AE ,  euphoria≠B-OSE_Labeled_AE ,  paranoid≠B-OSE_Labeled_AE   reaction≠I-OSE_Labeled_AE ;  rare:   aphasia≠B-OSE_Labeled_AE ,  nystagmus≠B-OSE_Labeled_AE ,  akathisia≠B-OSE_Labeled_AE  ( psychomotor≠B-OSE_Labeled_AE   restlessness≠I-OSE_Labeled_AE ),  stupor≠B-OSE_Labeled_AE ,  dementia≠B-OSE_Labeled_AE ,  diplopia≠B-OSE_Labeled_AE ,  drug≠B-OSE_Labeled_AE   dependence≠I-OSE_Labeled_AE ,  paralysis≠B-OSE_Labeled_AE ,  grand≠B-OSE_Labeled_AE   mal≠I-OSE_Labeled_AE   convulsion≠I-OSE_Labeled_AE ,  hypotonia≠B-OSE_Labeled_AE ,  myoclonus≠B-OSE_Labeled_AE ,  psychotic≠B-OSE_Labeled_AE   depression≠I-OSE_Labeled_AE ,  withdrawal≠B-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE ,  serotonin≠B-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE .

    Respiratory≠B-NonOSE_AE   System≠I-NonOSE_AE   :  frequent:   cough≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE ,  sinusitis≠B-OSE_Labeled_AE ;  infrequent:   epistaxis≠B-OSE_Labeled_AE ,  bronchitis≠B-OSE_Labeled_AE ,  asthma≠B-OSE_Labeled_AE ,  pneumonia≠B-OSE_Labeled_AE ;  rare:   asphyxia≠B-OSE_Labeled_AE ,  laryngitis≠B-OSE_Labeled_AE ,  pneumothorax≠B-OSE_Labeled_AE ,  hiccup≠B-OSE_Labeled_AE .

    Skin≠B-NonOSE_AE   and≠I-NonOSE_AE   Appendages≠I-NonOSE_AE   :  frequent:   pruritus≠B-OSE_Labeled_AE ,  rash≠B-OSE_Labeled_AE ;  infrequent:   acne≠B-OSE_Labeled_AE ,  exfoliative≠B-OSE_Labeled_AE   dermatitis≠I-OSE_Labeled_AE ,  dry≠B-OSE_Labeled_AE   skin≠I-OSE_Labeled_AE ,  herpes≠B-OSE_Labeled_AE   simplex≠I-OSE_Labeled_AE ,  alopecia≠B-OSE_Labeled_AE ;  rare:   urticaria≠B-OSE_Labeled_AE ,  herpes≠B-OSE_Labeled_AE   zoster≠I-OSE_Labeled_AE ,  skin≠B-OSE_Labeled_AE   hypertrophy≠I-OSE_Labeled_AE ,  seborrhea≠B-OSE_Labeled_AE ,  skin≠B-OSE_Labeled_AE   ulcer≠I-OSE_Labeled_AE .

    Special≠B-NonOSE_AE   Senses≠I-NonOSE_AE   :  infrequent:   eye≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  abnormality≠B-OSE_Labeled_AE   of≠I-OSE_Labeled_AE   accommodation≠I-OSE_Labeled_AE ,  conjunctivitis≠B-OSE_Labeled_AE ,  deafness≠B-OSE_Labeled_AE ,  keratoconjunctivitis≠B-OSE_Labeled_AE ,  lacrimation≠B-OSE_Labeled_AE   disorder≠I-OSE_Labeled_AE ,  angle≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  closure≠I-OSE_Labeled_AE   glaucoma≠I-OSE_Labeled_AE ,  hyperacusis≠B-OSE_Labeled_AE ,  ear≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ;  rare:   blepharitis≠B-OSE_Labeled_AE ,  partial≠B-OSE_Labeled_AE   transitory≠I-OSE_Labeled_AE   deafness≠I-OSE_Labeled_AE ,  otitis≠B-OSE_Labeled_AE   media≠I-OSE_Labeled_AE ,  taste≠B-OSE_Labeled_AE   loss≠I-OSE_Labeled_AE ,  parosmia≠B-OSE_Labeled_AE .

    Urogenital≠B-NonOSE_AE   System≠I-NonOSE_AE   :  frequent:   urinary≠B-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE ;  infrequent:   kidney≠B-OSE_Labeled_AE   calculus≠I-OSE_Labeled_AE ,  cystitis≠B-OSE_Labeled_AE ,  dysuria≠B-OSE_Labeled_AE ,  urinary≠B-OSE_Labeled_AE   incontinence≠I-OSE_Labeled_AE ,  urinary≠B-OSE_Labeled_AE   retention≠I-OSE_Labeled_AE ,  vaginitis≠B-OSE_Labeled_AE ,  hematuria≠B-OSE_Labeled_AE ,  breast≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  amenorrhea≠B-OSE_Labeled_AE ,  dysmenorrhea≠B-OSE_Labeled_AE ,  leukorrhea≠B-OSE_Labeled_AE ,  impotence≠B-OSE_Labeled_AE ;  rare:   polyuria≠B-OSE_Labeled_AE ,  urethritis≠B-OSE_Labeled_AE ,  metrorrhagia≠B-OSE_Labeled_AE ,  menorrhagia≠B-OSE_Labeled_AE ,  abnormal≠B-OSE_Labeled_AE   ejaculation≠I-OSE_Labeled_AE ,  breast≠B-OSE_Labeled_AE   engorgement≠I-OSE_Labeled_AE ,  breast≠B-OSE_Labeled_AE   enlargement≠I-OSE_Labeled_AE ,  urinary≠B-OSE_Labeled_AE   urgency≠I-OSE_Labeled_AE .

   Other Adverse Events Observed During Postmarketing Evaluation of REMERON

  Adverse events reported since market introduction, which were temporally (but not necessarily causally) related to mirtazapine therapy, include cases of the  ventricular≠B-OSE_Labeled_AE   arrhythmia≠I-OSE_Labeled_AE   Torsades≠B-OSE_Labeled_AE   de≠I-OSE_Labeled_AE   Pointes≠I-OSE_Labeled_AE . In the majority of these cases, however, concomitant drugs were implicated.

 Cases of severe  skin≠B-OSE_Labeled_AE   reactions≠I-OSE_Labeled_AE , including  Stevens≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  Johnson≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE ,  bullous≠B-OSE_Labeled_AE   dermatitis≠I-OSE_Labeled_AE ,  erythema≠B-OSE_Labeled_AE   multiforme≠I-OSE_Labeled_AE  and  toxic≠B-OSE_Labeled_AE   epidermal≠I-OSE_Labeled_AE   necrolysis≠I-OSE_Labeled_AE  have also been reported.

  Increased≠B-OSE_Labeled_AE   creatine≠I-OSE_Labeled_AE   kinase≠I-OSE_Labeled_AE   blood≠I-OSE_Labeled_AE   levels≠I-OSE_Labeled_AE  and  rhabdomyolysis≠B-OSE_Labeled_AE  have also been reported.

